कार्बामाज़ेपिन और ओलैंज़ापिन और फ्लुओक्सेटिन का इंटरैक्शन

Known hypersensitivity to tricyclic antidepressants ( 4 )

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope.

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity.

Consider reducing the dose of CNS depressants or EQUETRO when using these drugs concomitantly.

…voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide, nicotinamide, olanzapine, omeprazole, oxybutynin, quinine, quinupristin, ticlopidine, troleandomycin, valproate, verapamil, zileuton.

Inducers of 1A2 — Carbamazepine therapy (200 mg BID) causes an approximate 50% increase in the clearance of olanzapine.

Higher daily doses of carbamazepine may cause an even greater increase in olanzapine clearance [see Drug Interactions ( 7.7 )] .

Carbamazepine : Potential for elevated carbamazepine levels and clinical anticonvulsant toxicity ( 7.7 )

Phenytoin : Potential for elevated phenytoin levels and clinical anticonvulsant toxicity ( 7.7 )

This increase is likely due to the fact that carbamazepine is a potent inducer of CYP1A2 activity.